Skip header and navigation

2 records – page 1 of 1.

Impact of a statewide childhood vaccine program in controlling hepatitis A virus infections in Alaska.

https://arctichealth.org/en/permalink/ahliterature96313
Source
Vaccine. 2010 Jul 14;
Publication Type
Article
Date
Jul-14-2010
Author
Rosalyn J Singleton
Sarah Hess
Lisa R Bulkow
Louisa Castrodale
Ginger Provo
Brian J McMahon
Author Affiliation
Arctic Investigations Program, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), Anchorage, AK, United States; Alaska Native Tribal Health Consortium, Anchorage, AK, United States.
Source
Vaccine. 2010 Jul 14;
Date
Jul-14-2010
Language
English
Publication Type
Article
Abstract
Historically, Alaska experienced cyclic hepatitis A virus (HAV) epidemics, and the HAV rate among Alaska Native people was significantly higher than among other racial/ethnic groups. We evaluated the impact of universal childhood vaccination, initiated in 1996, on HAV epidemiology in Alaska by analyzing HAV cases reported to the State of Alaska. HAV incidence in all age groups declined 98.6% from 60.0/100,000 in 1972-1995 to 0.9/100,000 in 2002-2007. The largest decrease (99.9%) was in Alaska Native people, whose incidence (0.3) in 2002-2007 was lower than the overall US 2007 rate (1.0). Among age groups, the decrease (99.8%) among children aged 0-14 years was the largest. Routine childhood vaccination has nearly eliminated HAV infection in Alaska.
PubMed ID
20637769 View in PubMed
Less detail

Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014.

https://arctichealth.org/en/permalink/ahliterature295354
Source
Euro Surveill. 2018 Oct; 23(40):
Publication Type
Journal Article
Date
Oct-2018
Author
Prabhu P Gounder
Anders Koch
Ginger Provo
Astrid Lovlie
Josefine Lundberg Ederth
Maria Axelsson
Chris P Archibald
Brendan Hanley
Angie Mullen
Myrna Matheson
David Allison
Henrik Trykker
Thomas W Hennessy
Markku Kuusi
Vladimir Chulanov
Brian J McMahon
Author Affiliation
Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, U.S. Centers for Disease Control and Prevention (CDC), Anchorage, Alaska, USA.
Source
Euro Surveill. 2018 Oct; 23(40):
Date
Oct-2018
Language
English
Publication Type
Journal Article
Abstract
We summarised available hepatitis C virus (HCV) surveillance data for 2012-14 from Arctic/sub-Arctic countries/regions. We sent a HCV data collection template by email to public health authorities in all jurisdictions. Population statistics obtained from census sources for each country were used to estimate rates of reported acute and chronic/undifferentiated HCV cases. Seven countries with Arctic regions (Canada, Denmark, Finland, Greenland, Norway, Sweden and the United States, represented by the state of Alaska), including three Canadian territories and one province, as well as 11 Russian subnational Arctic regions, completed the data collection template. Data on acute HCV infection during 2014 was available from three Arctic countries and all Russian Arctic regions (rate range 0/100,000 population in Greenland, as well as Nenets and Chukotka Automous Okrugs (Russian subnational Arctic regions) to 3.7/100,000 in the Russian Republic of Komi). The rate of people with chronic/undifferentiated HCV infection in 2014 ranged from 0/100,000 in Greenland to 171.2/100,000 in Alaska. In most countries/regions, the majority of HCV-infected people were male and aged 19-64 years. Differences in surveillance methods preclude direct comparisons of HCV surveillance data between Arctic countries/regions. Our data can inform future efforts to develop standardised approaches to HCV surveillance in the Arctic countries/regions by identifying similarities/differences between the surveillance data collected.
Notes
Cites: Lancet. 2011 Aug 13;378(9791):571-83 PMID 21802134
Cites: Addict Sci Clin Pract. 2013 Dec 13;8:20 PMID 24330568
Cites: Euro Surveill. 2008 May 22;13(21):null PMID 18761967
Cites: Lancet Infect Dis. 2016 Dec;16(12):1409-1422 PMID 27615026
Cites: Int J Circumpolar Health. 2013 Jul 17;72:null PMID 23971016
Cites: Ann Intern Med. 2014 Mar 4;160(5):293-300 PMID 24737271
Cites: Alaska Med. 2007;49(2 Suppl):193-203 PMID 17929632
Cites: J Viral Hepat. 2014 May;21 Suppl 1:60-89 PMID 24713006
Cites: Euro Surveill. 2015 Apr 02;20(13):17-24 PMID 25860392
Cites: MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453-8 PMID 25950251
Cites: Harm Reduct J. 2013 May 07;10:7 PMID 23651646
Cites: J Hepatol. 2014 Nov;61(1 Suppl):S45-57 PMID 25086286
Cites: Emerg Infect Dis. 2008 Jan;14(1):18-24 PMID 18258072
Cites: Hepatology. 2013 Apr;57(4):1333-42 PMID 23172780
PubMed ID
30301489 View in PubMed
Less detail